SCHEMBL746724

SCHEMBL746724

COc1cc(O)c(C(=O)C=Cc2ccc(C)cc2)c(OC)c1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 6/20 0.85
NFKB1 P19838 1/20 0.85
DPP4 P27487 1/20 0.85
NFKB2 Q00653 1/20 0.85
RELA Q04206 1/20 0.85
CYP3A4 P08684 5/20 0.79
MAPT P10636 5/20 0.79
KMT2A Q03164 4/20 0.79
TP53 P04637 2/20 0.79
ATM Q13315 1/20 0.79
HSD17B10 Q99714 1/20 0.79
MKNK2 Q9HBH9 1/20 0.77
TDP1 Q9NUW8 3/20 0.77
MEN1 O00255 3/20 0.77
KDM4E B2RXH2 2/20 0.77
HPGD P15428 2/20 0.77
MCL1 Q07820 1/20 0.77
USP2 O75604 1/20 0.77
ALDH1A1 P00352 1/20 0.77
ALOX15 P16050 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL744395 1.00 ABCG2 (0.85) ABCG2NFKB1DPP4NFKB2RELA
Flavokawain A SCHEMBL29349587 0.92 ABCG2 (1.00) ABCG2NFKB1DPP4NFKB2RELA
Flavokawain C SCHEMBL30384247 0.92 NFKB1 (1.00) ABCG2NFKB1DPP4NFKB2RELA
Flavokawain C SCHEMBL144231 0.92 NFKB1 (1.00) ABCG2NFKB1DPP4NFKB2RELA
Flavokawain C SCHEMBL25201341 0.92 NFKB1 (1.00) ABCG2NFKB1DPP4NFKB2RELA
Flavokawain A SCHEMBL25209870 0.92 ABCG2 (1.00) ABCG2NFKB1DPP4NFKB2RELA
Flavokawain C SCHEMBL144230 0.92 NFKB1 (1.00) ABCG2NFKB1DPP4NFKB2RELA
Flavokawain A SCHEMBL2289181 0.92 ABCG2 (1.00) ABCG2NFKB1DPP4NFKB2RELA
Flavokawain A SCHEMBL2289188 0.92 ABCG2 (1.00) ABCG2NFKB1DPP4NFKB2RELA
SCHEMBL19183198 0.92 ABCG2 (0.88) ABCG2NFKB1DPP4NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
CN-115433073-A Preparation method and application of kava piperine B analogue 兰州大学 2022-12-06 CN disclosed
EP-2429292-B1 COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER GEORGIA STATE UNIV RESEARCH FOUNDATION (US) 2019-04-03 EP disclosed
WO-2017132135-A1 ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-08-03 WO disclosed
US-20120121692-A1 COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER SHANDONG UNIVERSITY (CN) 2012-05-17 US disclosed
EP-2429292-A1 COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR THE TREATMENT OF CANCER Georgia State University Research Foundation, Inc. (US) 2012-03-21 EP disclosed
WO-2010129858-A1 COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR THE TREATMENT OF CANCER GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION (US) 2010-11-11 WO disclosed
WO-2007115181-A9 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEM CO (US) 2008-04-03 WO disclosed
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof EASTMAN CHEMICAL COMPANY 2007-11-01 US disclosed
WO-2007115181-A2 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEMICAL COMPANY (US) 2007-10-11 WO disclosed
US-4605674-A VIRICIDES HOFFMANN-LA ROCHE INC. (US) 1986-08-12 US disclosed
US-4327088-A ANTIVIRAL AGENTS HOFFMANN-LA ROCHE INC. (US) 1982-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof ABCC4, NCOA4, NR4A3 ABCG2 5/4885NFKB1 1115/4885DPP4 1159/4885
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B ABCG2 1606/4885NFKB1 1669/4885DPP4 4226/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 ABCG2 3622/4885NFKB1 2437/4885DPP4 3670/4885
US-20120121692-A1 COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER CDK6, CDK5, CDK4 ABCG2 2761/4885NFKB1 832/4885DPP4 3309/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 ABCG2 3622/4885NFKB1 2437/4885DPP4 3670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.